Moderna , Inc. (NASDAQ:MRNA) President Hoge Stephen has recently engaged in a series of transactions involving the company's stock, according to the latest SEC filings. On May 29, 2024, Stephen sold a total of 341 shares of Moderna common stock at an average price of $144.50, totaling over $49,000.
The sale followed the vesting of restricted stock units (RSUs), which are commonly awarded to company executives as part of their compensation package. The RSUs vested on May 28, 2024, and were immediately converted into common stock on a one-for-one basis, resulting in an additional 610 shares in Stephen's direct ownership. However, these newly acquired shares did not result in a net gain for Stephen's holdings, as they were used to cover tax withholding obligations arising from the RSU vesting.
It's important to note that the sales executed by Stephen are part of a mandated process under Moderna's equity incentive plans, where executives are required to sell a portion of their vested shares to cover tax liabilities – a transaction often referred to as a "sell to cover." This means that the sale does not necessarily reflect a discretionary trading decision by Stephen.
In addition to his direct holdings, Stephen also has indirect interests in Moderna shares. Footnotes in the SEC filing disclose that a portion of Moderna's common stock is owned by a trust for the benefit of Stephen's spouse and children. While Stephen's spouse is a trustee of this trust, Stephen disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
After these recent transactions, Stephen's direct ownership in Moderna stands at 1,472,118 shares, excluding the indirect holdings through the trust.
Investors often monitor insider transactions as they can provide insights into executives' perspectives on the company's current valuation and future prospects. However, it's crucial to consider the context of such transactions, as they may be influenced by personal financial planning, tax considerations, or compensation structures, rather than purely by the executive's outlook on the company's performance.
InvestingPro Insights
Amid the recent insider transactions at Moderna, Inc. (NASDAQ:MRNA), investors are closely observing the company's financial health and market performance. According to real-time data, Moderna's market capitalization stands at a solid $58.06 billion. This valuation comes despite a challenging period reflected in the significant revenue decline over the last twelve months as of Q1 2024, with a decrease of 65.78%. Additionally, the company's gross profit margin during the same timeframe was notably negative at -70.27%, indicating cost pressures exceeding revenue.
On the upside, Moderna's stock has demonstrated resilience with a remarkable price total return of 34.09% over the last month and an even more impressive 60.36% over the last three months. This performance aligns with one of the InvestingPro Tips highlighting a large price uptick over the last six months, culminating in a 90.37% return. Investors considering Moderna's stock should also note that the company holds more cash than debt on its balance sheet, which is a reassuring sign of financial stability.
For those interested in further insights, InvestingPro Tips also reveal that analysts have revised their earnings upwards for the upcoming period, suggesting potential optimism about Moderna's future performance. With these mixed indicators, it's clear that Moderna presents a nuanced investment profile. For a deeper analysis of Moderna and access to additional tips, investors can explore https://www.investing.com/pro/MRNA. There are currently 14 additional tips available on InvestingPro to help guide investment decisions. Remember to use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.